DoW Neurofibromatosis Investigator-Initiated Research Award
About
Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Investigator-Initiated Research Award (IIRA) supports high-impact research that addresses a critical need and has the potential to make important contributions to the field of neurofibromatosis disorders or advance patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project. Distinctive Features: This award mechanism offers two funding levels based on participation in two optional features: • Open Science Initiative: Catalyzes research for neurofibromatosis through early access to data and data sharing within the neurofibromatosis community. • Optional Qualified Collaborator: Encourages collaborative research between basic scientists and clinical researchers, and between academic and biotechnology scientists. The funding levels are defined as follows: • Level 1: Applications without an optional feature. • Level 2: Applications including one of the optional features.
The DoW Neurofibromatosis Investigator-Initiated Research Award (IIRA) supports innovative research addressing critical needs in neurofibromatosis disorders. This grant is designed for researchers across academic institutions, biotechnology companies, and clinical settings who are committed to advancing the understanding and treatment of neurofibromatosis. The program funds high-impact research projects across all phases, excluding clinical trials, that have the potential to make meaningful contributions to the field or improve patient care. Researchers should apply if they have preliminary or published data demonstrating the relevance of their proposed work to neurofibromatosis research. The award offers flexible funding structures through two levels: Level 1 for standard applications and Level 2 for applications incorporating optional features such as participation in the Open Science Initiative for data sharing or collaboration between basic scientists and clinical researchers. This mechanism encourages cross-disciplinary partnerships and commitment to advancing the neurofibromatosis research community. If you're conducting neurofibromatosis research and seek funding to advance your investigations, this award provides an opportunity to accelerate your work and contribute to improved outcomes for patients with neurofibromatosis disorders.
Funding Facts
● Applications openDeadline
September 22, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by application level and cycle
Deadline
2026-09-22
Grant Type
federal
Application Cycle
Annual (Fiscal Year 2026 deadline: September 22, 2026)
Best For
Researchers in neurofibromatosis, academic institutions, biotech companies, clinical researchers, and interdisciplinary research teams
Frequently Asked Questions
Who is eligible for DoW Neurofibromatosis Investigator-Initiated Research Award?
Eligibility criteria are not fully specified in the available information. Typically, these awards support researchers at academic institutions, non-profit research organizations, and biotechnology companies. For complete and current eligibility requirements, including any institutional or researcher qualifications, visit the official Department of Defense Congressionally Directed Medical Research Programs (CDMRP) website or the grant announcement for fiscal year 2026.
How much funding does DoW Neurofibromatosis Investigator-Initiated Research Award provide?
The specific funding amounts are not provided in the available information. Funding levels may vary depending on whether your application includes optional features such as the Open Science Initiative or a Qualified Collaborator component. Contact the CDMRP or review the official FY26 NFRP announcement for current funding ranges.
How do I apply for DoW Neurofibromatosis Investigator-Initiated Research Award?
Applications are typically submitted through the CDMRP's electronic submission system. The application deadline for FY26 is September 22, 2026. You'll need to submit a research proposal that includes preliminary and/or published data relevant to neurofibromatosis. Your application should clearly articulate the critical need your research addresses and its potential impact. For detailed application instructions, submission requirements, and the official portal, visit the Department of Defense Congressionally Directed Medical Research Programs website.
What can DoW Neurofibromatosis Investigator-Initiated Research Award funding be used for?
Funding supports high-impact research addressing critical needs in neurofibromatosis across any phase of research, excluding clinical trials. Research may be derived from laboratory discovery, population-based studies, clinical observations, or preliminary data. The award encourages both basic science investigations and applied research that advances understanding of neurofibromatosis disorders or improves patient care. Optional features such as the Open Science Initiative and collaborative partnerships between basic and clinical researchers are incentivized through higher funding levels.
Last updated: July 5, 2026